• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness.

作者信息

Muzevich Katie M, Chohan Hadi, Grinnan Daniel C

出版信息

Crit Care. 2014 Oct 7;18(5):523. doi: 10.1186/s13054-014-0523-z.

DOI:10.1186/s13054-014-0523-z
PMID:25673176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4331447/
Abstract

Pulmonary arterial hypertension (PAH) is commonly treated with pulmonary arteriolar vasodilator therapy. When a patient on PAH medication is admitted to intensive care, determining how to manage their medication during the critical illness is often complicated. There may be considerations related to the inability to take medication by mouth, related to acute renal failure or acute liver injury, related to altered mental status or delirium, or related to hypotension and bacteremia. Decisions of how to manage these medications can have a major impact on the patient's clinical course. Presently, provider experience is the major tool in navigating the decisions regarding these medications. In this review, we offer our recommendations of how to manage PAH patients with critical illness who are on PAH medications. These recommendations include how to deliver medications via feeding tubes, how to dose medications in the setting of acute renal failure or acute liver failure, and how to manage medications during hypotension or when a tunneled catheter needs to be removed.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5f5/4331447/cba295d9daf3/13054_2014_523_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5f5/4331447/cba295d9daf3/13054_2014_523_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5f5/4331447/cba295d9daf3/13054_2014_523_Fig1_HTML.jpg

相似文献

1
Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness.
Crit Care. 2014 Oct 7;18(5):523. doi: 10.1186/s13054-014-0523-z.
2
Beyond the evidence: treating pulmonary hypertension in the intensive care unit.超越证据:重症监护病房中肺动脉高压的治疗
Crit Care. 2014 Oct 16;18(5):524. doi: 10.1186/s13054-014-0524-y.
3
Pulmonary arterial hypertension: a current review of pharmacological management.肺动脉高压:药物治疗现状综述
Pneumonol Alergol Pol. 2016;84(1):47-61. doi: 10.5603/PiAP.a2015.0084. Epub 2015 Dec 23.
4
Pulmonary hypertension in the intensive care unit. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.重症监护病房中的肺动脉高压。小儿肺动脉高压诊断与治疗专家共识声明。欧洲小儿肺血管疾病网络,得到国际心脏和肺移植学会(ISHLT)及德国儿科和青少年医学协会(DGPK)认可。
Heart. 2016 May;102 Suppl 2:ii57-66. doi: 10.1136/heartjnl-2015-307774.
5
Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.吸入伊洛前列素联合口服西地那非治疗重度肺动脉高压患者可延缓肺移植需求。
Transplant Proc. 2013 Jul-Aug;45(6):2347-50. doi: 10.1016/j.transproceed.2013.03.040.
6
[Cardio-pulmonary disorders associated with collagen vascular disease].
Nihon Rinsho. 2009 Mar;67(3):543-9.
7
Management of pulmonary vasodilator therapy in three pregnancies with pulmonary arterial hypertension.三例肺动脉高压妊娠患者的肺血管扩张剂治疗管理
J Obstet Gynaecol Res. 2017 May;43(5):935-938. doi: 10.1111/jog.13279. Epub 2017 Feb 14.
8
An evidence-based approach to the management of pulmonary arterial hypertension.一种基于证据的肺动脉高压管理方法。
Curr Opin Cardiol. 2006 Jul;21(4):385-92. doi: 10.1097/01.hco.0000231410.07426.9b.
9
Advances in prostacyclin therapy for pulmonary arterial hypertension.
Crit Care Nurse. 2004 Apr;24(2):42-8, 50-4.
10
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].[5型磷酸二酯酶抑制剂治疗肺动脉高压]
Anadolu Kardiyol Derg. 2010 Sep;10 Suppl 2:16-8. doi: 10.5152/akd.2010.125.

引用本文的文献

1
Inhaled epoprostenol for management of acute respiratory failure and pulmonary vascular disease.吸入依前列醇治疗急性呼吸衰竭和肺血管疾病
Pulm Pharmacol Ther. 2025 Jun 11;90:102374. doi: 10.1016/j.pupt.2025.102374.
2
Management Considerations for Pulmonary Arterial Hypertension Pharmacotherapy in the Intensive Care Unit.重症监护病房肺动脉高压药物治疗的管理考量
Pharmacy (Basel). 2023 Sep 13;11(5):145. doi: 10.3390/pharmacy11050145.
3
Keep the Right in Mind-A Focused Approach to Right Ventricle-Predominant Cardiogenic Shock.

本文引用的文献

1
Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension.比较吸入性一氧化氮和吸入性前列环素在肺动脉高压患者中的急性血液动力学效应。
Pulm Circ. 2013 Jan;3(1):68-73. doi: 10.4103/2045-8932.109916.
2
Causes and circumstances of death in pulmonary arterial hypertension.肺动脉高压的死亡原因和情况。
Am J Respir Crit Care Med. 2013 Aug 1;188(3):365-9. doi: 10.1164/rccm.201209-1640OC.
3
Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
牢记右心——右心室为主型心源性休克的聚焦治疗方法
Life (Basel). 2023 Jan 30;13(2):379. doi: 10.3390/life13020379.
4
Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging.在接受磁共振成像的患者中使用经美国食品药品监督管理局批准的一氧化氮吸入给药系统的理由。
Med Devices (Auckl). 2021 Jan 7;14:1-7. doi: 10.2147/MDER.S265099. eCollection 2021.
5
Acute Right Ventricular Dysfunction in Intensive Care Unit.重症监护病房中的急性右心室功能障碍。
Biomed Res Int. 2017;2017:8217105. doi: 10.1155/2017/8217105. Epub 2017 Oct 19.
6
Beyond the evidence: treating pulmonary hypertension in the intensive care unit.超越证据:重症监护病房中肺动脉高压的治疗
Crit Care. 2014 Oct 16;18(5):524. doi: 10.1186/s13054-014-0524-y.
Arch Bronconeumol. 2013 Mar;49(3):128-9. doi: 10.1016/j.arbres.2012.09.003. Epub 2012 Nov 3.
4
High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil.肺动脉高压患者静脉应用曲前列尼尔治疗后革兰氏阴性杆菌血流感染发生率高。
Arch Bronconeumol. 2012 Dec;48(12):443-7. doi: 10.1016/j.arbres.2012.06.005. Epub 2012 Jul 31.
5
Acquired liver injury in the intensive care unit.
Anesthesiology. 2012 Oct;117(4):898-904. doi: 10.1097/ALN.0b013e318266c6df.
6
The end-of-life experience for a cohort of patients with pulmonary arterial hypertension.肺动脉高压患者队列的临终体验。
J Palliat Med. 2012 Oct;15(10):1065-70. doi: 10.1089/jpm.2012.0085. Epub 2012 Jul 30.
7
Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure.因右心衰竭住院的肺动脉高压患者肾功能恶化与预后不良。
Congest Heart Fail. 2012 May-Jun;18(3):151-7. doi: 10.1111/j.1751-7133.2011.00275.x. Epub 2012 Jan 23.
8
Stability of an extemporaneously prepared tadalafil suspension.他达拉非混悬剂的稳定性。
Am J Health Syst Pharm. 2012 Apr 1;69(7):592-4. doi: 10.2146/ajhp110034.
9
Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome.吸入一氧化氮治疗与急性呼吸窘迫综合征幸存者长期肺功能之间的关联。
Crit Care. 2012 Dec 12;16(2):R36. doi: 10.1186/cc11215.
10
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.从 REVEAL 注册研究评估肺动脉高压诊断后患者的长期生存。
Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460.